Abstracts Archive - Page 821 of 2425 - ACR Meeting Abstracts

Abstract Number: 939 • 2019 ACR/ARP Annual Meeting
A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis
Richard Furie¹, Gustavo Aroca ², Analía Alvarez ³, Hilda Fragoso-Loyo ⁴, Elizabeth Zuta Santillán ⁵, Brad Rovin ⁶, Thomas Schindler ⁷, Imran Hassan ⁸, Matthew Cascino ⁹, Jay P. Garg ¹⁰ and Ana Malvar ¹¹, ¹Northwell Health, Great Neck, NY, ²Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia, ³CEMIC, Buenos Aires, Argentina, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, ⁵Instituto de Ginecología y Reproducción, Lima, Peru, ⁶The Ohio State University Medical Center, Columbus, OH, ⁷F. Hoffmann-La Roche AG, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., San Fransisco, CA, ¹⁰Genentech, Inc., South San Francisco, CA, ¹¹Hospital Fernandez; Organización Maedica de Investigación, Buenos Aires, Argentina
Background/Purpose: Randomized trials in lupus nephritis (LN) of type I anti-CD20 monoclonal antibodies failed to demonstrate superiority over standard of care alone. NOBILITY (NCT02550652) is…
Abstract Number: 940 • 2019 ACR/ARP Annual Meeting
Response to Placebo in Randomized Clinical Trials with Biologics in Non-renal, Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Pooled Analysis
Konstantinos Tselios¹, Laura Wakani ², Dafna Gladman ³, Jiandong Su ⁴ and Murray Urowitz ⁴, ¹University Health Network, University of Toronto, Toronto, Canada, ²University Health Network, Toronto, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Most randomized controlled trials (RCTs) with biologic medicines in systemic lupus erythematosus (SLE) failed to reach their respective end-points with the rates of the…
Abstract Number: 941 • 2019 ACR/ARP Annual Meeting
Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity
Yemil Atisha Fregoso¹, Susan Malkiel ², Kristina Harris ³, Sai Kanaparthi ³, Margie Byron ⁴, Linna Ding ⁵, Dawn Smilek ⁶, David Wofsy ⁷, Maria Dall'Era ⁸, Cynthia Aranow ¹ and Betty Diamond ⁹, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institute for Medical Research, Manhasset, ³Immune Tolerance Network, Bethesda, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁶Immune Tolerance Network, San Francisco, CA, ⁷UCSF, San Francisco, ⁸University of California, San Francisco, San Francisco, CA, ⁹Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Despite the relevance of B cells in lupus, two clinical trials of anti-CD20 failed to meet primary endpoints in patients with lupus and lupus…
Abstract Number: 942 • 2019 ACR/ARP Annual Meeting
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Daniel Wallace¹, Roberta Alexander ², Tyler O'Malley ³, Arezou Khosroshahi ⁴, Mehrnaz Hojjati ⁵, Konstantinos Loupasakis ⁶, Jeffrey Alper ⁷, Yvonne Sherrer ⁷, Maria Fondal ⁷, Rajesh Kataria ⁸, Tami Powell ², Claudia Ibarra ², Sonali Narain ⁹, Elena Massarotti ¹⁰, Arthur Weinstein ² and Thierry Dervieux ², ¹Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA, ⁴Emory University, Atlanta, GA, ⁵Department of Rheumatology, Loma Linda University, Loma Linda, CA, ⁶MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁷BendCare Rheumatology, Naples, FL, ⁸Southern Ohio Rheumatology, Wheelersburg, OH, ⁹Northwell Health, Great Neck, Long Island, NY, ¹⁰Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Cell-Bound Complement Activation Products (CB-CAPs) in multianalyte assay panel (MAP) is a diagnostic immunology laboratory test with established clinical validity in distinguishing systemic lupus…
Abstract Number: 943 • 2019 ACR/ARP Annual Meeting
A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
Sarfaraz Hasni¹, Sarthak Gupta ², Michael Davis ³, Elaine Poncio ⁴, Yenealem Temesgen-Oyelakin ⁴, Phillip Carlucci ⁴, Xinghao Wang ⁴, Mohammad Naqi ⁴, Martin Playford ⁵, Rishi Goel ⁴, Xiaobai Li ⁶, Ann Biehl ⁴, Isabel Ochoa-Navas ⁴, Zerai Manna ⁴, Yinghui Shi ⁷, Don Thomas ⁸, Jinguo Chen ⁹, Angélique Biancotto ⁹, Richard Apps ⁹, Foo Cheung ⁹, Yuri Kotliarov ⁹, Ashley Babyak ⁶, Katie Stagliano ⁹, John Tsang ⁹, Wanxia Tsai ¹⁰, Laura Vian ¹⁰, Nathalia Gazaniga ⁴, Valentina Giudice ⁴, Stephen Brooks ¹¹, Meggan Mackay ¹², Peter Gregersen ¹³, Betty Diamond ¹⁴, Nehal Mehta ¹⁵, Alan Remaley ⁵, John O'Shea ¹⁶, Massimo Gadina ¹⁰ and Mariana Kaplan ¹⁶, ¹National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, ³NIAMS/NIH, Bethesda, MD, ⁴NIAMS/NIH, Bethesda, ⁵NHLBI/NIH, Bethesda, ⁶Clinical Center/NIH, Bethesda, ⁷Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹NIAID/NIH, Bethesda, ¹⁰Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ¹¹Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ¹²Feinstein Institute for Medical Research, New York, ¹³Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁴Feinstein Institutes of Medical Research, Manhasset, NY, ¹⁵National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ¹⁶National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda
Background/Purpose: A pharmacologic intervention that modulates JAK/STAT signaling pathways represents a novel approach for the treatment of Systemic Lupus Erythematosus (SLE). In animal models of…
Abstract Number: 944 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study
Richard Furie¹, Ian Bruce ², Thomas Dörner ³, Manuel Gustavo Leon ⁴, Piotr Leszczyński ⁵, Murray Urowitz ⁶, Birgit Haier ⁷, Claire Brittain ⁸, Jiajun Liu ⁹, Catherine Barbey ¹⁰ and Christian Stach ⁷, ¹Northwell Health, Great Neck, NY, ²University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Investigaciones Clínicas, Lima, Peru, ⁵Poznań University of Medical Sciences, Poznań, Poland, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹Biogen, Cambridge, MA, ¹⁰Biogen, Baar, Switzerland
Background/Purpose: Dapirolizumab pegol (DZP) is a polyethylene glycol-conjugated Fab’ fragment, which targets CD40 ligand and is in development for the treatment of systemic lupus erythematosus…
Abstract Number: 945 • 2019 ACR/ARP Annual Meeting
Comparison of Clinical Manifestations in IgG4 Related Disease Patients with/without Aortitis/Periaortitis and Periarteritis: A Prospective Cohort Study of 587 Patients with IgG4-RD Disease
Linyi Peng ¹, Wen Zhang ² and Panpan Zhang¹, ¹Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China (People's Republic)
Background/Purpose: We aimed to clarify the clinical features of IgG4-related disease (IgG4-RD) with/without aortitis/periaortitis and periarteritis (PAO/PA), and evaluate the treatment efficacy of patients with…
Abstract Number: 946 • 2019 ACR/ARP Annual Meeting
Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study
Gulen Hatemi¹, Alfred Mahr ², Mitsuhiro Takeno ³, Doyoung Kim ⁴, Melike Melikoglu ⁵, Sue Cheng ⁶, Shannon McCue ⁷, Maria Paris ⁶, Mindy Chen ⁸ and Yusuf Yazici ⁹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Behcet's Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Nippon Medical School, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University – Cerrahpasa, Behçet’s Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ⁶Celgene Corporation, Summit, ⁷Celgene Corporation, Summit, NJ, ⁸Celgene Corporation, Berkeley Heights, NJ, ⁹New York University School of Medicine, New York
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful, recurrent oral ulcers (OU) that can impair quality of life (QoL). Apremilast (APR),…
Abstract Number: 947 • 2019 ACR/ARP Annual Meeting
TNF Inhibitor Treatment and Dramatic Stroke Risk Reduction in Patients with Deficiency of Adenosine Deaminase 2
Ryan Laird¹, Patrycja Hoffmann ², Karyl Barron ², Deborah Stone ², Michele Nehrebecky ³, Anne Jones ², Tina Romeo ², Camilo Toro ³, Arianne Soldatos ⁴, Cornelia Cudrici ³, Daniel Kastner ² and Amanda Ombrello ², ¹National Institues of Health, Bethesda, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, ⁴NIH/NINDS, Bethesda
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease caused by biallelic loss-of-function mutations in the ADA2 gene . Over 60 pathogenic…
Abstract Number: 948 • 2019 ACR/ARP Annual Meeting
Relapsing Cryoglobulinemic Vasculitis Following Successful HCV Eradication by Interferon-Free Direct Acting Antivirals, an International Multicenter Study
Mohamed Tharwat Hegazy¹, Ahmed Fayed ¹, Tarek El Shabony ¹, Marcella Visentini ², David Saadoun ³, Patrice Cacoub ³ and Gaafar Ragab ¹, ¹Cairo University, Cairo, Egypt, Cairo, Egypt, ²Sapienza University of Rome, Rome, Italy, Rome, Italy, ³AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France
Background/Purpose: Interferon-free Direct Acting Antiviral (DAA) combinations proved to be effective for the treatment of HCV induced Cryoglobulinemic Vasculitis (HCV-Cryovas). Some reports showed relapses of…
Abstract Number: 949 • 2019 ACR/ARP Annual Meeting
Assessment of Femoral Vein Wall Thickness with Doppler Ultrasound Can Be a Diagnostic Tool for Behcet’s Disease
Fatma Alibaz-Oner¹, RABIA ERGELEN ², YASIN YILDIZ ³, Ayten Yazici ⁴, AYDAN MUTIS ⁵, ZEYNEP ERTURK ³, MUSTAFA ALDAG ⁶, Ayşe Cefle ⁷, Bahar Artim-Esen ⁸, GONCA MUMCU ⁹, TULIN ERGUN ¹⁰ and Haner Direskeneli ¹¹, ¹Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, ²MARMARA UNIVERSITY, SCHOOL OF MEDICINE, RADIOLOGY, ISTANBUL, Turkey, ³MARMARA UNIVERSITY, SCHOOL OF MEDICINE, RHEUMATOLOGY, ISTANBUL, Turkey, ⁴Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, ⁵MARMARA UNIVERSITY, SCHOOL OF MEDICINE, RHEUMATOLOGY, ISTANBUL, Tuvalu, ⁶BAHCESEHIR UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF CARDIOVASCULAR SURGERY, ISTANBUL, Turkey, ⁷Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ⁸Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁹Marmara, University, Department of Health Management, Marmara University School of Health Sciences, Istanbul, Turkey, ISTANBUL, Turkey, ¹⁰MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DERMATOLOGY, Istanbul, Istanbul, Turkey, ¹¹Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Behcet's disease(BD) is a uniqe systemic vasculitis mainly involving venous vessels in contrast to other systemic vasculitides. Diagnosing BD is a challenge, especially in…
Abstract Number: 950 • 2019 ACR/ARP Annual Meeting
Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease
Xiao-qing Liu¹, Xiaojie Liu ², Nalin Lai ³, Ting Cheng ¹, Chong Gao ⁴ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²Taiyuan University of Technology, Taiyuan, China (People's Republic), ³Shanxi Medical University, Taiyuan, China (People's Republic), ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Behcet’s disease (BD) is a chronic multisystemic disease characterized by muco-cutaneous and ocular manifestations, with central nervous system, vascular and/or gastro-intestinal involvement. Several studies…
Abstract Number: 951 • 2019 ACR/ARP Annual Meeting
Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences
Candace Feldman¹, Chang Xu ¹ and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Nearly 25% of patients with SLE are hospitalized each year often for outcomes that may have been avoided if patients had received sustained, high…
Abstract Number: 952 • 2019 ACR/ARP Annual Meeting
Rate of Thirty-Day Readmissions in Systemic Lupus Erythematosus Rivals Congestive Heart Failure and Exceeds the General Medicare Population
Ann Chodara¹, Xing Wang ¹, Fangfang Shi ¹, Shivani Garg ¹, Ryan Powell ¹, Maria Schletzbaum ¹, Ann Sheehy ¹, Amy Kind ¹ and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Medicare measures readmissions within 30 days of hospitalization across several conditions as a marker of care quality. While not currently a reporting condition, in…
Abstract Number: 953 • 2019 ACR/ARP Annual Meeting
Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data
Robin Dore¹, Lawrence Chang ², Yuanyuan Ji ³, Suying Li ³, Jenya Antonova ² and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Chronic Disease Research Group, Minneapolis, MN, ⁴Stanford University, Stanford, CA
Background/Purpose: In RA patients not meeting treat-to-target goals despite treatment with a biologic (b)DMARD, ACR guidelines1 recommend using other targeted immunomodulators (TIM): TNF-α inhibitor (TNFi),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].